AI takes the lead in the lab
The day's biggest story was a marriage of artificial intelligence and big-money biotech. Insilico Medicine, a clinical-stage firm based in Massachusetts, signed a research collaboration with South Korea's SK Biopharmaceuticals to discover new medicines using AI — a pact the companies value at up to $2.5 billion. The deal puts software at the front of the drug-hunting process rather than the back, and it lands as the field's ambitions keep widening.
A second AI bet pushed into stranger territory. Abiologics, a startup founded by life-science venture firm Flagship, is turning AI toward so-called mirror-image proteins — a kind of medicine nature doesn't normally make. Together, the two stories sketch a field moving from incremental assists to designing molecules from scratch.
A $10.8 billion acquisition starts to pay off
Merck got the validation it paid for. The company said Monday morning that the lead program from its $10.8 billion acquisition of Prometheus Biosciences succeeded in its first Phase 3 trial, beating placebo. It's an early but meaningful return on one of the industry's larger recent buyouts, and a reminder that the splashiest deals are ultimately judged in the clinic.
The IPO window opens — for a few
The market for new biotech stock offerings is heating up, but with conditions attached. At BIO's annual meeting, investors and life-science bankers predicted an acceleration in new listings, even as the optimism came wrapped in caveats. The window is cracking open, the consensus went, but only for a chosen few companies with the right story.
Regulators shift — in two directions
The FDA reversed another of its drug rejections, clearing gene-therapy developer Regenxbio to resubmit its treatment. It fits a broader pattern of the agency walking back earlier denials. On the policy side, the Trump administration's Department of Health and Human Services launched a sweeping initiative to expand and accelerate clinical trials — a push to get more medicines tested, faster.
AI in the clinic: promise and friction
Away from drug discovery, AI's medical debut looked uneven. On the research front, a new quantum-inspired approach aims to match cancer treatment to a patient's full molecular makeup, tailoring care to a person's entire genetic picture. And in a striking first, the startup Coherence Neuro began human testing of a cancer-detecting brain implant, with three people now fitted with the devices.
The administrative reality was rockier. Reporting captured the split screen: breakthroughs in the lab, headaches in the clinic, with Medicare's effort to lean on AI running into trouble. The technology is moving deeper into medicine on both ends — and the friction is showing where it meets day-to-day care.
Funding the fight
Finally, a researcher at the University of California, San Diego won a $5.6 million NIH Avant-Garde Award aimed at preventing HIV, hepatitis C and overdose — a reminder that even amid the AI gold rush, the grant-funded basics of public health still draw real money.
Taken together, it was a day defined by AI's growing reach, a marquee acquisition paying off, and regulators recalibrating on both approvals and trials.